Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Larger DA diameter was significantly related to this low systemic blood flow in the early hours after birth. [13] By the time the PDA became clinically apparent (mean 72 hours), the infants were ...

Italy: A new study published in Pediatric Research has questioned the long-standing practice of fluid restriction in preterm ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

More than one in 10 infants worldwide are born preterm, many with complications: Nearly 1 million die each year. This is the single largest cause of death in children around the world before their ...

Once a PDA is suspected or confirmed, the 2 main questions are (1) how to treat and (2) when to treat a particular infant This clinical controversy recently was the subject of an excellent systematic ...